MedTrace Logo

Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT

NCT02872662 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 308

Last updated 2026-04-24

No results posted yet for this study

Summary

This study aims to develop highly sensitive methods for early detection of relapse based on the patients unique mutations. Initially, a mutational screen is being performed. Primers directed against these mutations will be constructed and presence of mutations will be followed in bone marrow and blood frequently after transplantation.

Conditions

Sponsors & Collaborators

  • Helsinki University Central Hospital

    collaborator OTHER

  • Nordic MDS Group

    lead NETWORK

Principal Investigators

  • Eva Hellström-Lindberg, Prof · Karolinska Institutet

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2021-11-22
Completion
2021-11-22

Countries

  • Denmark
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02872662 on ClinicalTrials.gov